SIAIS100

Cat. No.:	HY-152036
Molecular Formula:	$C_{44}H_{50}ClF_2N_9O_5S$
Molecular Weight:	890.44
Target:	PROTACs; Bcr-Abl
Pathway:	PROTAC; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SIAIS100 is a potent BCR-ABL PROTAC degrader with an DC_{50} value of 2.7 nM. SIAIS100 can be used to research chronic myeloid leukemia (CML)[1].
IC_{50} & Target	DC_{50}: 2.7 nM [1]
In Vitro	SIAIS100 exhibits anti-proliferative activity against K562 cells with an IC_{50} value of 12 nM[1]. SIAIS100 degrades BCR-ABL with degradation ratio of 81.78% and 91.20% at 5 nM and 100 nM, respectively[1]. SIAIS100 (100 nM; 8 h) significantly decreases BCR-ABL in K562 cells[1]. SIAIS100 (100 nM; 6 h) induced sustained and robust BCR-ABL degradation and maintained a durable cellular response after drug removal[1]. SIAIS100 (1-1000 nM) significantly degrade mutation G250E/T315I dose-dependently accompanied by the inhibition of BCR-ABL signaling assessed by the level of p-BCR-ABL in 32D cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	K562
Concentration:	100 nM
Incubation Time:	8 h
Result:	Significantly decreases BCR-ABL.

REFERENCES

[1]. Liu H, et al. Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor. Eur J Med Chem. 2022 Dec 15;244:114810.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA